Biomarker and preclinical data support SEZ6 as a potential therapeutic target in small cell lung cancer management.

Investigators of the CEMI-LUNG study (NCT05363319) enrolled an unselected, real-world population of more than 200 patients ...

A biologics license application (BLA) for etentamig (ABBV-383) has been submitted to the FDA for the treatment of adults with ...

Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.

In KEYNOTE-412, early ctDNA clearance was linked with better survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.

Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.

At the Big Ten CRC Summit, VK Gadi, MD, PhD, explained why functional drug testing and genomic profiling should be used ...

Translating laboratory discoveries into clinical benefit for patients with breast cancer increasingly depends on combining ...

In October 2026, the Vatican announced that Pope Leo XIV had undergone a right lower lobectomy to remove a lung nodule that ...

The next-generation KRAS G12C inhibitor divarasib significantly prolonged progression-free survival (PFS) and overall ...

Adding ribociclib (Kisqali) to a nonsteroidal aromatase inhibitor (NSAI) produced an overall survival (OS) benefit vs NSAI ...

The investigators concluded that AZUR-1 “demonstrates sustained clinical complete responses after dostarlimab monotherapy in ...